PureForm Global, Inc.
Richard Nanula is an accomplished executive with extensive experience in finance, strategy, and corporate management across various industries. Currently, Richard serves as Chief Executive Officer and Executive Chairman at Lucy Scientific Discovery, involved in psychedelic drug manufacturing and development. At PureForm Global, Inc., Richard has also held the role of Chief Executive Officer since December 2019. Richard's previous positions include Senior Advisor at Tarsus Entertainment, Principal at Colony Capital, and EVP Finance & Strategy & CFO at Amgen, where significant acquisitions totaling $18 billion were executed. Richard's leadership at Starwood Hotels & Resorts as President and COO resulted in the integration of multiple entities into the world's largest hospitality company. Additionally, Richard's tenure at The Walt Disney Company included roles that contributed to the company's revenue growth from $2 billion to over $20 billion and facilitated the landmark acquisition of Capital Cities/ABC.
This person is not in any teams
PureForm Global, Inc.
PureForm is a biosciences company focused on the discovery and production of pure cannabinoids for use in treating disease and promoting wellness. PureForm uses its proprietary technology to produce rare cannabinoids that are safe, legal, and effective for wellness and pharmaceutical applications. Our synthetic platform can quickly and sustainably produce almost any molecule found in nature. Enabling superior supply chain economics while creating sustainable solutions for both natural and novel compounds. Our research and clean chemistry production platform enables a sustainable, safe, cost effective, commercial scale supply chain option for both pharmaceutical and consumer products companies to address widespread consumer adoption. PureForm uses Cyclic Terpene Assembly™ (CTA), it’s proprietary technology for assembling cannabinoids from naturally occurring terpenes. The Cannome™ is PureForm’s catalogue of cannabinoids - all pure molecules, synthesized using Natural Product Chemistry. PureForm CBD is PureForm’s first cannabinoid to go from bench to commercial scale cGMP production. PureForm’s proprietary platform is unlocking the potential of over 100 cannabinoids. Each cannabinoid is chirally pure and stereochemically identical to cannabinoids extracted from hemp and cannabis. PureForm has completed commercial scale-up of CBD and can produce metric ton quantities today. In addition to the production of cannabinoids found in hemp and cannabis, PureForm is also working on routes of synthesis to develop unique and novel compounds and cannabinoid-like derivatives targeting the endocannabinoid system that have the potential to be pharmaceutically relevant. Our Cyclic Terpene Assembly™ (CTA) technology delivers a high-performance alternative to agricultural and biosynthetic based production of molecules in a cost efficient and sustainable format.